Patents by Inventor Donald Martin Carter

Donald Martin Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
    Patent number: 10925957
    Abstract: Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 23, 2021
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Jr., Christopher Austin Darby, Harold Kleanthous
  • VACCINES INTELLIGENTLY PRODUCED BY EPITOPE RECOMBINATION (VIPER) FOR INFLUENZA
    Publication number: 20200237898
    Abstract: Provided herein are optimized recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Application
    Filed: September 21, 2016
    Publication date: July 30, 2020
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn Ross, Terrianne Maiko Wong, Donald Martin Carter, Jr., Corey John Crevar
  • Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
    Patent number: 10548965
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Oregon Health & Science University, Sanofi Pasteur, Inc.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Characterization of influenza vaccines
    Patent number: 10485864
    Abstract: Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: November 26, 2019
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn Ross, Terianne Maiko Wong, Donald Martin Carter, Jr.
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA
    Publication number: 20190175721
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: January 25, 2019
    Publication date: June 13, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, JR., Christopher Austin Darby, Harold Kleanthous
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR HUMAN AND AVIAN H5N1 INFLUENZA
    Publication number: 20190111126
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 18, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
    Patent number: 10220086
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 5, 2019
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES
    Publication number: 20180271972
    Abstract: Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 27, 2018
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn ROSS, Terianne Maiko WONG, Donald Martin CARTER, Jr.
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA
    Publication number: 20170368164
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous